Editing Interferon beta-1a (section)

====Avonex====
Avonex was approved in the US in 1996,<ref name="Approval of Avonex">{{cite news | title=F.D.A. Approves a Biogen Drug for Treating Multiple Sclerosis | website=[[The New York Times]] | date=8 May 1996 | url=https://www.nytimes.com/1996/05/18/business/fda-approves-a-biogen-drug-for-treating-multiple-sclerosis.html | access-date=16 January 2021 | archive-date=22 January 2021 | archive-url=https://web.archive.org/web/20210122104645/https://www.nytimes.com/1996/05/18/business/fda-approves-a-biogen-drug-for-treating-multiple-sclerosis.html | url-status=live }}</ref> and in the European Union in 1997, and is registered in more than 80 countries worldwide.{{cn|date=October 2020}} It is the leading MS therapy in the US, with around 40% of the overall market, and in the European Union, with around 30% of the overall market.{{citation needed|date=April 2015}} It is produced by the [[Biogen]] [[biotechnology]] company, originally under competition protection in the US under the [[Orphan Drug Act]].

Avonex is sold in three formulations, a lyophilized powder requiring reconstitution, a pre-mixed liquid syringe kit, and a pen; it is administered via [[intramuscular injection]].<ref name="Avonex FDA label">{{cite web | title=Avonex- interferon beta-1a kit Avonex Pen- interferon beta-1a injection, solution Avonex- interferon beta-1a injection, solution | website=DailyMed | date=30 March 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-8063b69ea0e1 | access-date=1 October 2020 | archive-date=25 March 2021 | archive-url=https://web.archive.org/web/20210325060926/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-8063b69ea0e1 | url-status=live }}</ref>